Vitamin E and alpha-lipoic acid may extend survival in end-stage renal disease
by Newsletter Editor
People with end-stage renal disease on hemodialysis often have increased oxidative stress and inflammation. In this study, 85 people on hemodialysis took 400 IU of vitamin E per day, 600 mg of alpha-lipoic acid per day, these two antioxidants together, or a placebo. After two months, levels of the inflammatory factor, interleukin-6, which can predict survival, were much lower in the vitamin E and alpha-lipoic acid groups, compared to placebo. Commenting on the results, doctors said in a future trial they would like to raise the doses during a longer study to see if the benefits of taking vitamin E and alpha-lipoic acid increase.